Neuropsychiatric effects of cardiovascular drug therapy

Cardiology in Review

Volumn 11, Issue 2, 2003, Pages 73-93

  Keller, Seth ^a   Frishman, William H ^b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Adverse effects; Neuropsychiatric symptoms; Neurotoxicity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CHLORDIAZEPOXIDE; CLONIDINE; DIAZEPAM; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; GANGLION BLOCKING AGENT; GUANETHIDINE; HYDRALAZINE; LEVODOPA; METHYLDOPA; METHYSERGIDE; NITROPRUSSIDE SODIUM; OXPRENOLOL; PRAZOSIN; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BRADYKINESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIGITALIS INTOXICATION; DOUBLE BLIND PROCEDURE; DROWSINESS; EJACULATION DISORDER; ELECTROCONVULSIVE THERAPY; EUPHORIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOMANIA; HYPOTENSION; IMPOTENCE; INSOMNIA; KORSAKOFF PSYCHOSIS; LETHARGY; MAJOR CLINICAL STUDY; MANIA; MENTAL DISEASE; META ANALYSIS; MULTICENTER STUDY; MUSCLE RIGIDITY; MUSCLE WEAKNESS; NERVOUSNESS; NEUROTOXICITY; NIGHTMARE; OPIATE ADDICTION; PANIC; PARANOIA; PARKINSONISM; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; TREMOR; VERTIGO; VISUAL HALLUCINATION; WERNICKE ENCEPHALOPATHY; WITHDRAWAL SYNDROME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM; DIURETICS; HUMANS; MENTAL DISORDERS;

EID: 0037344546     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CRD.0000053453.89776.2D     Document Type: Article

References (253)

1. Keller S, Frishman WH, Epstein J: Neuropsychiatric manifestations of cardiovascular drug therapy. Heart Dis 1999;1:241-254.
2. Paykel ES, Fleminger R, Watson JP: Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982;2:14-39.
3. Pottash ALC, Black HR, Gold MR: Psychiatric complications of antihypertensive medications. J Nerv Ment Dis 1981;169:430-438.
4. Haynes RB, Sackett DL, Taylor DW, et al: Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978;299:741-744.
5. Raft D, Spencer RF, Tooney T, et al: Depression in medical outpatients: use of the Zung scale. Dis Nerv Sys 1977;38:999-1004.
6. Dollery CT, Emslie-Smith D, Milne MD: Guanethidine in the treatment of hypertension. Lancet 1960;3:381-387.
7. Seedat YK, Pillay VKG: Further experience with guanethidine - a clinical assessment of 103 patients. South Afr Med J 1966;1:140-142.
8. Stocks AE, Robertson A: The long-term therapy of severe hypertension with guanethidine. Am Heart J 1967;73: 569-570.
9. Evanson JM, Seers HTN: Comparison of bretylium tosylate with guanethidine in the treatment of severe hypertension. Lancet 1960;3:387-389.
10. Goodwin FK, Ebart MH, Bunney WE: Mental effects of reserpine in man: a review. In: Shader RI, ed. Complications of Medical Drugs. New York: Raven; 1972:73-101.
11. Rauch SL, Stern TA, Zusman RM: Neuropsychiatric considerations in the treatment of hypertension. Int J Psychiatry Med 1991;21:291-308.
12. Fries ED: Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 1954;251:1006.
13. Quetsch RM, Achor RWP, Litin EM, et al: Depressive reaction in hypertensive patients - a comparison of those treated with rauwolfia and those receiving no specific antihypertensive treatment. Circulation 1959;19:366-375.
14. Schroeder HA, Perry HM: Psychosis apparently produced by reserpine. JAMA 1955;159:839-840.
15. Kass I, Brown EC: Treatment of hypertensive patients with rauwolfia compounds and reserpine. JAMA 1955; 159:1513-1516.
16. Ayd FJ: Drug induced depression: fact or fallacy. N Y J Med 1958;58:354-356.
17. Wurzelmann J, Frishman WH, Aronson M, et al: Neuropsychological effects of antihypertensive drugs. Cardiol Clin 1987;5:689-701.
18. Barsa JA, Kline NS: Treatment of 200 disturbed psychotics with reserpine. JAMA 1955;158:110-113.
19. Maggs R, Ellison RM: Five year follow up of reserpine therapy in mental hospital practice. J Ment Sci 1960;106: 590-598.
20. Tooney G, Isberg EM, Gottlieb JS: The use of reserpine in an acute psychiatric setting. Arch Neurol Psychiatry 1959;81:325.
21. Flach FF: Clinical effectiveness of reserpine. Ann N Y Acad Sci 1955;61:161.
22. Gahgon LH: Ineffectiveness of chlorpromazine and rauwolfia serpentina preparations in the treatment of depression. Dis Nerv Sys 1957;18:390-393.
23. Kinross-Wright V: Chlorpromazine and reserpine in the treatment of psychoses. Ann N Y Acad Sci 1955;61:174-182.
24. Adler S: Methyldopa induced decrease in mental activity. JAMA 1974;230:1428-1429.
25. Baekeland F, Lundwall L: Effects of methyldopa on sleep patterns in man. Electroenceph Clin Neurophysiol 1971; 31:269-273.
26. Thornton WE: Dementia induced by methyldopa with haloperidol. N Engl J Med 1976;294:1222.
27. Fullerton AG, Morton-Jenkins D: Methyldopa and depression. BMJ 1963;1:538-539.
28. Dubach VC: Methyldopa and depression. BMJ 1963;1: 261.
29. Strange RR: Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966;95:928-929.
30. Markhorn CH, Clark WG, Winters WD: Effects of alphamethyldopa and reserpine in Huntington's chorea, Parkinson's disease and other movement disorders. Life Sci 1963;9:697-705.
31. Paykel ES: Hallucinosis in combined methyldopa and pargyline. BMJ 1966;1:803.
32. Schwarz D, Michel D, Strian F: Depressive reaktioner unter antihypertensive behandlung. Arch Psychiatr Nerverkr 1973;218:41-50.
33. Gossop M: Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988;21: 253-259.
34. Gold MS, Redmond DE, Kleber HD: Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978;2:599-602.
35. Johnson JM: Psychiatric uses of antiadrenergic and adrenergic blocking drugs. J Nerv Ment Dis 1984;172:123-132.
36. Wilkins AJ, Jenkins WJ, Steiner JA: Efficacy of clonidine in treatment of alcohol withdrawal states. Psychopharmacology (Berl) 1983;81:78-80.
37. Baumgartner GR, Rowen RC: Clonidine versus chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 1987;147:1223-1226.
38. Cushman P: Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse 1988;7:17-28.
39. Robinson BJ, Robinson GM, Maling TJB, et al: Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 1989;13:95-98.
40. Ozdemir V, Brenner KE, Naranjo CA: Treatment of alcohol withdrawal syndrome. Ann Intern Med 1994;26:101-105.
41. Frishman WH, Ky T, Ismail A: Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapies. Heart Dis 2001;3:365-377.
42. Gourlay SG, Benowitz NL: Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
43. Cohen DJ, Young JG, Nathanson JA, et al: Clonidine in Tourette's syndrome. Lancet 1979;2:551-553.
44. Cohen DJ, Riddle MA, Leckman JF: Pharmacotherapy of Tourettes syndrome and associated disorders. Psychiatr Clin North Am 1992;15:109-129.
45. O'Carroll RE, Moffoot A, Embier KP, et al: Korsakoff's syndrome, cognition and clonidine. Psychol Med 1993; 23:341-347.
46. McEntee WJ, Mair RG: Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit. Ann Neurol 1980;7:466-470.
47. Wilens TE, Spencer TJ, Swanson JM, et al: Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999;38:614-619.
48. Comings DE, Comings BG, Tacket T, et al: The clonidine patch and behavior problems. J Am Acad Child Adolesc Psychiatry 1990;29:667-668.
49. Prince JB, Wilens TE, Biederman J, et al: Clonidine for sleep disturbance associated with the attention deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996;35:599-605.
50. Seno S, Shaw SM, Christian JE: Distribution and urinary excretion of furosemide in the rat. J Pharmacol Sci 1969; 58:935-938.
51. McLean J, Manchip S: Wernicke's encephalopathy induced by magnesium depletion. Lancet 1999;353:1768.
52. Lewis WH: Iatrogenic psychotic depressive reaction in hypertensive patients. Am J Psychiatry 1971;127:1416-1417.
53. Okada F: Depression after treatment with thiazide diuretics for hypertension. Am J Psychiatry 1985;142:1101-1102.
54. Moss HB, Procci WR: Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. Gen Hosp Psychiatry 1982;4:121-129.
55. Williams GH, Croog SH, Levine S, et al: Impact of anti-hypertensive therapy on quality of life: effect of hydrochlorothiazide. J Hypertens Suppl 1987;5:S29-S35.
56. Trimmer E: Sex problems in practice - iatrogenic sex problems. Br Med J (Clin Res Ed) 1981;283:953-955.
57. Zhenchao G, Fratiglioni L, Zhu L, et al: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999;56:991-996.
58. Alarcon-Segovia D, Wakim KG, Worthington JW, et al: Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosus. Medicine 1967;46:1-35.
59. Benson D, Peterson LG, Bartay J: Neuropsychiatric manifestations of antihypertensive medications. Psychiatr Med 1983;1:205-214.
60. Chin DKF, Cho AK, Tse CY: Neuropsychiatric complications related to use of prazosin in patients with renal failure. BMJ 1986;293:1347.
61. 1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry 2000;61: 129-133.
62. Dimsdale JE, Newton RP, Joist T: Neuropsychological side effects of beta blockers. Arch Intern Med 1989;149: 514-525.
63. Keller S, Frishman WH, Nurenberg J: Neuropsychiatric effects of cardiovascular medications. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997:1053-1071.
64. Viadero JJ, Wong SH, White WB: Acute psychotic behavior associated with atenolol. Am J Psychiatry 1983;140: 1382.
65. Arber N: Delirium induced by atenolol. BMJ 1988;297: 1048.
66. Kramer BA: Severe confusion in a patient receiving electroconvulsive therapy and atenolol. J Nerv Ment Dis 1986;174:562-563.
67. Applegate WB, Pressel S, Wittes J, et al: Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly Program. Arch Intern Med 1994;154:2154-2160.
68. Gerstman BB, Jolson HM, Bauer M, et al: The incidence of depression in new users of beta-blockers and selective antihypertensives. J Clin Epidemiol 1996;49:809-815.
69. Frishman WH, Razin A, Swenciones C, et al: Update: Beta-adrenoceptor blockade in anxiety states: a new approach to therapy? Cardiovasc Rev Rep 1992;13:8-31.
70. Kathol RG, Noyes R, Slymen DJ, et al: Propranolol in chronic anxiety disorders. Arch Gen Psychiatry 1980;37: 1361-1365.
71. Lader M: Beta adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988;48:213-223.
72. Tyrer P: Current status of beta blocking drugs in the treatment of anxiety disorders. Drugs 1988;36:773-783.
73. Noyes R Jr: Beta adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 1985;8:119-132.
74. Brantigan CO, Brantigan TA, Joseph N: Effect of beta-blockade and beta-stimulation on stage fright. Am J Med 1982;72:88-94.
75. Anonymous: Consider beta-blockers when somatic symptoms of anxiety predominate. Drug Ther Perspect 1996; 8:9.
76. Liebowitz MR, Gorman JM, Fyer AJ, et al: Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257.
77. Lydiard RB, Brawman-Mitzner O, Ballenger JC: Recent developments in the psycho-pharmacology of anxiety disorders. J Consult Clin Psychol 1996;64:660-668.
78. Liebowitz MR, Schneier F, Campeas R, et al: Phenelzine vs. atenolol in social phobia. Arch Gen Psych 1992;49: 290-300.
79. Hoehn-Saric R, McLoed DR: Cardiac symptoms and anxiety disorders: contributing factors and pharmacologic treatment. Am J Cardiol 1987;60:68J-73J.
80. Krantz DS, Contrada RJ, LaRiccia PJ, et al: Effects of beta adrenergic stimulation and blockade on cardiovascular reactivity, affect and type A behavior. Psychosom Med 1987;49:146-158.
81. Prakash R, Campbell TW, Petrie WM: Psychoses with propranolol: a case report. Can J Psychiatry 1983;28:657-658.
82. Berlant JL: One more look at propranolol for the treatment of refractory schizophrenia. Schizophr Bull 1987; 13:705-714.
83. Hanssen T, Heyden T, Sundberg T, et al: Propranolol in schizophrenia: clinical metabolic and pharmacologic findings. Arch Gen Psychiatry 1988;37:685-690.
84. Peet M, Middlemiss DN, Yates RA: Propranolol in schizophrenia, II: clinical and biochemical aspects of combining propranolol with chlorpromazine. Br J Psychiatry 1981;138:112-117.
85. Perenyi A, Farkas A: Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry 1983;18:391-394.
86. Adler L, Angrist B, Peselow E, et al: A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986;149:42-45.
87. Ratey JJ, Sergi P, Polakoff S: Nadolol as a treatment of akathisia. Am J Psychiatry 1985;142:640-642.
88. Elliott FA: Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurol 1977; 1:489-491.
89. Brooke MM, Patterson DR, Questad KA, et al: The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil 1992;73:917-921.
90. Rosenbaum A, Hoge S: Head injury and marital aggression. Am J Psychiatry 1989;146:1048-1051.
91. Greendyke RM, Kanter DR: Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry 1986;47:423-426.
92. Greendyke RM, Berkner JP, Webster JC, et al: Treatment of behavioral problems with pindolol. Psychosomatics 1989;30:161-165.
93. Ratey JJ, Mikkelsen EJ, Smith GB, et al: Beta blockers in the severely and profoundly mentally retarded. J Clin Psychopharm 1986;6:103-107.
94. Weiler PJ, Mungas D, Bernick C: Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988;1:226-230.
95. Shankle W, Nielson K, Cotman C: Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995;9:233-237.
96. Fava M: Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-451.
97. Mattes JA: Psychopharmacology of temper outbursts: a review. J Nerv Ment Dis 1986;174:464-470.
98. Jacob MS, Zilm DH, MacLeod SM, et al: Propranolol-associated confused states during alcohol withdrawal. J Clin Psychopharmacol 1983;3:185-187.
99. Kraus ML, Gottlieb LD, Horwitz RI, et al: Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985;31:905-909.
100. Mayo-Smith MF: Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997;278:144-151.
101. Abernethy DR, Greenblatt DJ, Shader RI: Treatment of diazepam withdrawal syndrome with propranolol. Ann Intern Med 1981;94:354-355.
102. Tyrer P, Rutherford D, Huggett T: Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981;1:520-522.
103. Nurenberg JR: Intravenous nitroglycerine in the management of post-treatment hypertension during electroconvulsive therapy. J Nerv Ment Dis 1991;179:291-294.
104. Shiah IS, Yatham LN, Srisurapanont M, et al: Does the addition of pindolol accelerate the response to electroconvulsive therapy in patients with major depression? a double blind placebo controlled pilot study. J Clin Psychopharmacol 2000;20:373-378.
105. Artigas F, Perez V, Alvarez E: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51: 248-251.
106. Blier P, Bergeron R: Effectiveness of pindolol with selected anti-depressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-221.
107. Vinar O, Vinarova E, Horacek J: Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression. Homeostasis 1996;37:93-95.
108. Bakish D, Hooper CL, Thornton ME, et al: Fast onset - an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. Int Clin Psychopharmacol 1997;12:91-97.
109. Blier P, Bergeron R, de Montigny C: Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16: 333-338.
110. Berman RM, Darnell AM, Miller HM, et al: Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind placebo-controlled trial. Am J Psychiatry 1997;154:37-43.
111. Perez V, Gilaberte I, Faries D, et al: Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597.
112. Tome MB, Issac MT, Harte R, et al: Paroxetine and pindolol - a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89.
113. Zanardi R, Artigas F, Franchini L, et al: How long should pindolol be associated with paroxetine to improve antidepressant response? J Clin Psychopharmacol 1997;17: 446-450.
114. Bordet R, Thomas P, Dupuis B: Effect of pindolol onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double blind placebo controlled trial. Resau de Rechereche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998;155:1346-1351.
115. Hoschl C: Do calcium antagonists have a place in the treatment of mood disorders? Drugs 1991;42:721-729.
116. Dassylva B: Verapamil may cause depression. Can J Psychiatry 1993;38:299-300.
117. Lyndon RW, Johnson G, McKeough G: Nifedipine induced depression. Br J Psychiatry 1991;36:447-448.
118. Jacobsen FM, Sack DA, James SP: Delirium induced by verapamil. Am J Psychiatry 1987;144:248.
119. Fogelman J: Verapamil caused depression, confusion and impotence. Am J Psychiatry 1988;145:380.
120. Ahmad S: Nifedipine-induced acute psychosis. J Am Geriatr Soc 1994;32:408.
121. Binder EF, Cayabyab L, Ritchie DJ, et al: Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Arch Intern Med 1991;151:373-374.
122. Busche CJ: Organic psychosis caused by diltiazem. J R Soc Med 1988;81:296-297.
123. Palat GK, Movahed A: Secondary mania associated with diltiazem. Clin Cardiol 1986;9:39.
124. Dubovsky SL: Calcium antagonists in manic-depressive illness. Neuropsychobiology 1993;27:184-192.
125. Hollister LE, Garza-Trevino ES: Calcium channel blockers in psychiatry. Prog Drug Res 1996;47:279-292.
126. Balon R, Ramesh C: Calcium channel blockers for anxiety disorders? Ann Clin Psych 1996;8:215-220.
127. Dubovsky SL, Buzan RD: Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997;58:224-242.
128. Hollister LE, Garza-Trevino ES: Calcium channel blockers in psychiatric disorders: A review of the literature. Can J Psychiatry 1999;44:658-664.
129. Dubovsky SL, Franks RD, Lifschitz M, et al: Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982;139:502-504.
130. Gitlin MJ, Weiss J: Verapamil as maintenance treatment in bipolar illness: a case report. J Clin Psychopharmacol 1984;4:341-343.
131. Pollack MH, Rosenbaum JF: Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 1987; 22:779-782.
132. Jacques RM, Cox SJ: Verapamil in major (psychotic) depression. Br J Psychiatry 1991;158:124-125.
133. Johnson BA, Cowen PJ: Calcium channel blockade and resistant bipolar depression. Irish J Psychol Med 1991;8: 50-51.
134. Dose M, Emrich HM, Cording-Tommel C, et al: Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241-243.
135. Giannini AJ, Loiselle RH, Price WA, et al: Comparison of antimanic efficacy of clonidine and verapamil. J Clin Pharmacol 1985;25:307-308.
136. Dubovsky SL, Franks RD, Allen S, et al: Calcium antagonists in mania: a double blind study of verapamil. Psychiatry Res 1986;18:309-320.
137. Hoschl C, Kozemy J: Verapamil in affective disorders: a controlled double blind study. Biol Psychiatry 1989;25: 128-140.
138. Garza-Trevino ES, Overall JE, Hollister LE: Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149: 121-122.
139. Walton SA, Berk M, Brokk S: Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. J Clin Psychiatry 1996;57:543-546.
140. Caillard V: Treatment of mania using a calcium antagonist - preliminary trial. Neuropsychobiology 1985;14:23-26.
141. Brunet G, Cerlich B, Robert P, et al: Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropsychopharmacol 1990;13:224-228.
142. Eccleston D, Cole AJ: Calcium-channel blockade and depressive illness. Br J Psychiatry 1990;156:889-891.
143. Lindelius R, Nilsson CG: Flunarizine as maintenance treatment of a patient with bipolar disorder. Am J Psychiatry 1992;149:139.
144. Barton BM, Gitlin MJ: Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol 1987;7: 101-103.
145. Mogilnicka E, Czyzak A, Maj J: Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test: antidepressants facilitate nifedipine action. Eur J Pharmacol 1987;138:413-416.
146. Wells BG: Verapamil in the treatment of schizophrenia. Drug Intell Clin Pharm 1990;24:838-840.
147. Tourjman SV, Bloom DM, Nair NPV: Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull 1987;23:227-229.
148. Schepelern S, Koster A: Verapamil in the treatment of severe schizophrenia. Acta Psychiatr Scand 1987;75:557-558.
149. Reiter S, Adler L, Angrist B, et al: Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 1989;50:26-27.
150. Pickar D, Wolkowitz OM, Doran AR: Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987;44:113-118.
151. Grebb JA, Shelton RC, Taylor EH, et al: A negative, double blind, placebo controlled clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry 1986;21: 691-694.
152. Price WA, Pascarzi GA: Use of verapamil to treat negative symptoms in schizophrenia. J Clin Psychopharmacol 1987;7:357.
153. Price WA: Antipsychotic effects of verapamil in schizophrenia. J Clin Psychiatry 1987;9:225-230.
154. Goldstein JA: Calcium channel blockers in the treatment of panic disorders. J Clin Psychiatry 1985;46:546.
155. Klein E, Uhde TW: Controlled study of verapamil for the treatment of panic disorder. Am J Psychiatry 1988;145: 431-434.
156. Goldstein JA: Nifedipine treatment of Tourettes syndrome. J Clin Psychiatry 1984;45:360.
157. Walsh TL, Lavenstein B, Licamele WI, et al: Calcium antagonists in the treatment of Tourette's disorder. Am J Psychiatr 1986;143:1467-1468.
158. Ban TA, Morey I, Aguglia E, et al: Nimodipine in the treatment of old age dementia. Prog Neuropharmacol Biol Psychiatr 1990;14:525-551.
159. Tollefson GD: Short-term effects of the calcium channel blocker nimodipine in the management of primary degenerative dementia. Biol Psychiatr 1991;27:1133-1142.
160. Forette F, Seux M-L, Staeseen JA, et al: Prevention of dementia in randomized double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur). Lancet 1998;352:1347-1351.
161. Rodnitzky RL: Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 1999;57: 845-849.
162. Zubenko GS, Nixon RA: Mood elevating effects of captopril in depressed patients. Am J Psychiatry 1984;141: 110-111.
163. Croog SH, Levine S, Testa MA, et al: The effects of hypertensive therapy on quality of life. N Engl J Med 1986;314:1657-1664.
164. Dieken RF: Captopril treatment of depression. Biol Psychiatry 1986;21:1425-1428.
165. Germain L, Chouinard G: Treatment of unipolar recurrent major depression with captopril. Biol Psychiatry 1988; 23:637-641.
166. Germain L, Chouinard G: Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 1989;25:489-493.
167. Vuckovic A, Cohen BM, Zubenko GS: The use of captopril in treatment-resistant depression: an open trial. J Clin Psychopharmacol 1991;11:395-396.
168. Patten SB, Brager N, Sanders S: Manic symptoms associated with the use of captopril. Can J Psychiatry 1991;36: 314-315.
169. Gajula RP, Berlin RM: Captopril induced mania. Am J Psychiatry 1993;150:1429-1430.
170. Skop BP, Masterson BJ: Mania secondary to lisinopril therapy. Psychosomatics 1995;36:508-509.
171. Patterson JF: Depression associated with enalapril. South Med J 1989;82:402-403.
172. Gunduz H, Georges JL, Fleishman S: Quinapril and depression. Am J Psychiatr 1999;156:1114-1115.
173. Patten SB, Williams JVA, Love EJ: Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996;41:469-476.
174. Gillman MA, Sandyk R: Reversal of captopril-induced psychosis with naloxone. Am J Psychiatry 1985;142:270.
175. Haffner CA, Smith BS, Pepper C: Hallucinations as an adverse effect of angiotensin converting enzyme inhibition. Postgrad Med J 1993;69:240.
176. Riordan JF: Angiotensin converting enzyme inhibitors and alcohol abuse. EXS 1994;71:323-331.
177. Sudilovsky A, Cutler NR, Sramek JJ, et al: A pilot clinical trial of the angiotensin converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Dis Assoc Disord 1993;7:105-111.
178. Goldstein JA: Captopril in the treatment of psychogenic polydypsia. J Clin Psychiatry 1986;47:99.
179. Carvajal A, Lerida MT, Sanchez A, et al: ACE inhibitors and impotence: a case series from the Spanish Drug Monitoring System. Drug Saf 1995;13:130-131.
180. Phillips MI: Functions of angiotensin in the central nervous system. Ann Rev Physiol 1987;49:413-435.
181. Ranidive SA, Chen AX, Serajjuden AT: Relative lipophilicities and structural-pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharmacol Res 1992;9:1480-1486.
182. Cushman DW, Wang FL, Fung WC, et al: Differentiation of angiotensin converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989;2:294-306.
183. Amegui A, Penny EK, Rossor M, et al: Angiotensin converting enzyme in Alzheimers disease increased activity in caudate nucleus and cortical areas. J Neurochem 1982; 38:1490-1492.
184. Koller M, Krause HP, Hoffmeister F, et al: Endogenous brain angiotensin II disrupts passive avoidance behavior in rats. Neurosci Lett 1979;14:71-75.
185. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
186. Anonymous: Losartan. Med Lett Drugs Ther 1995;37:57-59.
187. Ahmad S: Losartan and reversible psychosis. Cardiology 1996;87:569-570.
188. Tronvik E, Stovner LJ, Helde G, et al.: Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289:65-69.
189. Roden DM: Antiarrhythmic drugs. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th Edition. New York: McGraw Hill; 2001:933-970.
190. Schubert DSP, Gabinet L: Psychosis induced by sustained release procainamide. Can Med Assoc J 1984;131: 1188-1190.
191. Rice H, Haltzman S, Tucek C: Mania associated with procainamide. Am J Psychiatry 1988;145:129-130.
192. Johnson AG, Day RO, Seldon WA: A functional psychosis precipitated by quinidine. Med J Aust 1990;153:47-49.
193. Deleu D, Schmedding E: Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. BMJ 1987;294: 1001-1002.
194. Gilbert GJ: Quinidine dementia. Am J Cardiol 1978;41: 791.
195. Billig N, Buongiorno P: Quinidine induced organic mental disorders. J Am Geriatr Soc 1985;33:504-506.
196. Ahmad S: Disopyramide-induced acute psychosis. Chest 1979;76:712.
197. Ahmad S: Disopyramide and impotence. South Med J 1980;73:958.
198. Lewis DO: Serendipitous relief with disopyramide of phobia for flying. Am J Psychiatry 1983;140:1387.
199. Pfeifer HJ, Greenblatt DJ, Koch-Weser J: Clinical use and toxicity of intravenous lidocaine (a report from the Boston Collaborative Drug Surveillance Program). Am Heart J 1976;92:168-173.
200. Wyman MG, Lalka D, Hammersmith L, et al: Multiple bolus technique for lidocaine administration during the first hours after an acute myocardial infarction. Am J Cardiol 1978;41:313-317.
201. Sarvay SM, Marke J, Steinberg MD, et al: "Doom anxiety" and delirium in lidocaine toxicity. Am J Psychiatry 1987; 144:159-163.
202. Lloyd B, Greenblatt D: Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension. J Clin Psychopharmacol 1981;1:394-398.
203. Bikadoroff G: Mental changes associated with tocainide, a new antiarrhythmic. Can J Psychiatry 1987;32:219-221.
204. Clarke CWF, El-Mahdi EO: Confusion and paranoia associated with oral tocainide. Postgrad Med J 1985;61:79-81.
205. Ramhamadany E, Mackenzie S, Ramsdale DR: Dysarthria and visual hallucinations due to flecainide toxicity. Postgrad Med J 1986;62:61-62.
206. Bennett MI: Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997;70:93-94.
207. Trohman RG, Castellanos D, Castellanos A, et al: Amiodarone-induced delirium. Ann Intern Med 1988;108:68-69.
208. Barry JJ, Franklin K: Amiodarone-induced delirium. Am J Psychiatry 1999;156:119.
209. Ambrose A, Salib B: Amiodarone-induced depression. Br J Psychiatry 1999;174:366-367.
210. Ahmad S: Amiodarone and sexual dysfunction. Am Heart J 1995;130:1320-1321.
211. Sweadner KJ: Overview: subunit diversity in the Na-K ATPase. In: Kaplan JH, DeWeer R, eds. The Sodium Pump: Structure, Mechanism and Regulation. New York: Rockefeller University Press; 1991:63-76.
212. Duroziez P: De delire et du coma digitaliques. Gaz Hebedo Med Chir 1874;11:780-785.
213. Smith HL: Cerebral manifestations of digitalis intoxication. Mayo Clin Proc 1938;13:574-575.
214. King L: Digitalis delirium. Ann Intern Med 1950;33: 1360-1372.
215. Smith H, Janz TG, Erker M: Digoxin toxicity presenting as altered mental status in a patient with severe chronic obstructive lung disease. Heart Lung 1992;21:78-80.
216. Eisendrath SJ, Sweeny MA: Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987;144:506-507.
217. Greenblatt DJ, Shader RI: Digitalis toxicity. In: Shader RI, ed. Psychiatric Complications of Medical Drugs. New York: Raven; 1972:25-47.
218. Patten SB, Love EJ: Neuropsychiatric adverse reactions: passive reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965-present). Int J Psychiatry Med 1994;24:45-62.
219. Wardle J: Cholesterol and psychological well being. J Psychosom Res 1995;39:549-562.
220. Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-314.
221. Rossouw JE, Lewis B, Rifkind BM: The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-1119.
222. Ravnskov U: Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ 1992; 305:15-19.
223. Smith GD, Song F, Sheldon TA: Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367-1373.
224. Law MR, Thompson SG, Wald NJ: Assessing possible hazards of reducing serum cholesterol. BMJ 1994;308: 373-379.
225. Jacobs D, Blackburn H, Higgins M, et al: Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992;86:1046-1060.
226. Frank JW, Reed DM, Grove JS, et al: Will lowering population levels of serum cholesterol affect total mortality? J Clin Epidemiol 1992;45:333-346.
227. Neaton TD, Blackburn H, Jacobs D, et al: Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490-1500.
228. Pekkanen J, Nissien A, Punsar S, et al: Serum cholesterol and the risk of accidental or violent death in a 25 year follow up. The Finnish Cohorts of the Seven Countries Study. Arch Intern Med 1989;149:1589-1591.
229. Smith GD, Shipley MJ, Marmot MG, et al: Plasma cholesterol concentrations and mortality: the Whitehall Study. JAMA 1994;267:70-76.
230. Markovitz JH, Smith D, Raczynski JM, et al: Lack of relations of hostility, negative affect, and high risk behavior with low plasma lipid levels in the Coronary Artery Risk Development in Young Adults Study. Arch Int Med 1997;157:1953-1959.
231. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
232. Shepherd J, Cobbe SM, Ford I, et al: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Group. N Engl J Med 1995;333:1301-1307.
233. Lines C: Hazards of reducing cholesterol. BMJ 1994;309: 541.
234. Muldoon MF, Barger SD, Ryan CM, et al: Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538-547.
235. Stewart RA, Sharples KJ, North FM, et al, for the LIPID Study Investigators: Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. Arch Intern Med 2000;160:3144-3152.
236. Wardle J, Rogers P, Judd P, et al: Randomized trial of the effects of cholesterol-lowering dietary treatment on psychological function. Am J Med 2000;108:547-553.
237. Downs JR, Oster G, Santanello NC, for the Air Force Coronary Atherosclerosis Prevention Study Research Group: HMG-CoA reductase inhibitors and quality of life. JAMA 1993;269:3107-3108.
238. Wardle J, Armitage J, Collins R, et al: Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. BMJ 1996;313:75-78.
239. Duits N, Bos FM: Depressive symptoms and cholesterol lowering drugs. Lancet 1993;341:114.
240. Kassler-Taub B, Woodward T, Markowitz JS: Depressive symptoms and pravastatin. Lancet 1993;341:371-372.
241. Lechleitner M, Hoppichler F, Konwalinka G, et al: Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet 1992;340:910.
242. Engelberg H: Low cholesterol and suicide. Lancet 1992; 339:727.
243. Schaefer EJ: HMG CoA reductase inhibitors for hypercholesterolemia. N Engl J Med 1988;319:1222-1223.
244. Barth JD, Kruisbrink OAE, VanDijk AL: Inhibitors of hydroxy-methylglutaryl coenzyme A reductase for treating hypercholesterolemia. BMJ 1990;301:669.
245. Simvastatin. Lancet 1992;339:547.
246. Rosenson RS, Goranson NL: Lovastatin-associated sleep and mood disorders. Am J Med 1993;95:548-549.
247. Vgontzas AN, Kales A, Bixler EO, et al: Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-737.
248. Roth T, Richardson GR, Sullivan JP, et al: Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992;15:426-432.
249. Botti RE, Triscari J, Pan HY, et al: Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991;14:256-261.
250. Jick H, Zornberg GL, Jick SS, et al: Statins and the risk of dementia. Lancet 2000;356:1627-1631.
251. Figueras A, Castel JM, LaPorte JR, et al: Gemfibrozil induced impotence. Ann Pharmacother 1993;27: 982.
252. Bharani A: Sexual dysfunction after gemfibrozil. BMJ 1992;305:693.
253. Schneider J, Kaffarnick H: Impotence in patients treated with clofibrate. Atherosclerosis 1975;21:455-457.